Introduction
============

Colorectal cancer (CRC) is the fourth most commonly diagnosed type of cancer as well as second leading cause of cancer-related death \[[@b1-crt-2014-066]\]. About one-fourth of all CRC patients have liver metastases at the time of their diagnosis \[[@b2-crt-2014-066],[@b3-crt-2014-066]\], and 20% of patients develop liver metastases after surgical resection of the primary tumor \[[@b2-crt-2014-066]\]. For patients with colorectal liver metastasis (CLM), hepatic resection is a potentially curative option \[[@b4-crt-2014-066]-[@b6-crt-2014-066]\], but only 20% of such patients are suitable for resection at presentation. As another option, chemotherapeutic agents such as oxaliplatin and irinotecan allow an additional 10%-20% of patients to undergo hepatic resection for initially unresectable CLM \[[@b7-crt-2014-066]-[@b9-crt-2014-066]\]. In addition, recent developments in surgical techniques, radiologic imaging, and chemotherapy are changing the definition of surgical resectability.

Previous studies have identified several risk factors that can be used to select patients suitable for hepatic resection \[[@b10-crt-2014-066]-[@b15-crt-2014-066]\]. Since 1996, 12 prognostic scoring systems have been developed \[[@b16-crt-2014-066]\]. All studies that developed scoring systems were based on retrospective data and proposed groups ranging in number from three to six. The studies were also based exclusively on patients who underwent surgical resections, and some of the methods were based on surgical-pathological factors that cannot be easily obtained. Given this background, reliable, easily accessible, and accurate clinical factors predicting outcomes need to be identified and consolidated in referred patients with CLM.

In this study, principal component analysis (PCA) was developed as a new stratification method for CLM using prognostic factors selected by multivariate analysis. We also compared PCA with the Fong\'s scoring method.

Materials and Methods
=====================

1. Patients
-----------

Analysis was conducted using prospective databases containing patients diagnosed with confined liver metastasis due to CRC at Severance Hospital of the Yonsei University Health System between 1989 and 2010. All patients were given a physical examination, and medical histories were collected. Serum laboratory tests and appropriate imaging studies, including computed tomographic (CT) or magnetic resonance (MR) imaging of the chest, abdomen, and pelvis, were done to evaluate the liver and check for extrahepatic disease. Patients also underwent colonoscopies to assess local recurrence of the primary tumor. After surgery, serial serum carcinoembryonic antigen (CEA) levels, CT imaging of the abdomen, and chest radiography were obtained for each patient every 3 to 4 months for 2 years, and every 6 months thereafter. For induction chemotherapy, response to chemotherapy was evaluated every 2 months by a multidisciplinary team that included surgeons, oncologists, and radiologists. The team used CT or MR imaging according to World Health Organization guidelines during the initial study period as well as the Response Evaluation Criteria in Solid Tumors during the final period. Patients responding to chemotherapy were reconsidered for surgery when the overall strategy achieved complete clearance of hepatic metastases.

2. Statistical method
---------------------

To stratify patients according to survival risk, we applied PCA. PCA is a simple, nonparametric statistical method that reduces data dimensionality by using an orthogonal transformation to convert correlated variables into uncorrelated variables, which are termed principal components. PCA has a lower or equal number of principal components compared to the number of original variables. Each principal component is represented in the form of linear combinations of original variables. Therefore, some value for each patient can be calculated according to the following formula, which we call the PCA score:
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, where V1, V2, V3 ... Vn are the values of original variables, whereas C1, C2, C3 ... Cn are coefficients of each of the variables.

We applied PCA to one patient group in order to determine the coefficient of each variable, and a PCA score was generated for each patient. The variables included in the PCA analysis were defined by multivariate Cox regression analysis. The patient groups were stratified into three groups by the lower (Q1) and upper (Q3) quartiles of the PCA score. The presence of significantly different survival patterns was then tested among these three patients groups.

To investigate the performance of the new PCA-based method, we explored the distribution of accuracy, specificity, and sensitivity. For this, we simulated the patient stratification process 100 times by resampling. The patients wer randomly divided into training (396 patients, 70%) and test set (170 patients, 30%) groups. PCA was applied to the training data set to determine the coefficient of each variable, and a PCA score was generated for each patient. The training set was then stratified into two groups based on the mean value of the PCA scores. Based on the final outcome (survival or death), accuracy, specificity, and sensitivity were calculated as follows:
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, where TP, TN, FP, and FN are true positive, true negative, false positive, and false negative, respectively.

Multivariate Cox regression was used to select candidate significant factors before PCA, and chi-square tests were used to test dependency between survival patterns and different risk groups. Statistical analyses were conducted using R ver. 2.12.0, and a p-value of \< 0.05 was considered statistically significant. The PCA algorithm was also performed using R.

3. Fong's risk score
--------------------

To analyze our patients by the Fong\'s method, the following five prognostic factors were assessed for each patient, and each factor scored one point: 1) lymph node-positive primary tumor; 2) disease-free interval (DFI) \< 12 months; 3) number of liver metastases \> 1; 4) preoperative CEA level of \> 200 ng/mL; 5) size of largest liver metastasis \> 5 cm. A total score between 0 and 5 points was obtained for each subject in the population, which was then divided into two risk groups: 0-2 points, low-risk group; 3-5 points, high-risk group.

Results
=======

1. Patient demographics
-----------------------

A total of 566 patients with liver-confined metastasis were included in this study. The median age at time of liver metastasis was 57.8 years. Colon was the primary site of metastasis in patients at 60.6%. Among 334 patients with initially unresectable CLM, 264 patients remained unresectable after chemotherapy, whereas 70 patients underwent liver resection after tumor response to induction treatment. Among them, lobectomy was performed in 31.4% of patients (n=22) and segmentectomy or wedge resection in 65.7% (n=46). Local treatment (radio frequency ablation \[RFA\]) was necessary in 40% of patients (n=28) to achieve complete resection. RFA was conducted when patients had anatomically ill-located lesions, insufficient hepatic reserves after surgery, or combined comorbidities that inhibited major surgery. The regimen of induction treatment consisted most often of fluorouracil and leucovorin alone (12.9%) or combination with oxaliplatin (58.6%), irinotecan (28.6%), or targeted agents (34.3%). Two hundred and thirty-two patients with initially resectable CLM underwent liver resection followed by adjuvant chemotherapy. Lobectomy was performed in 37 patients (15.9%), segmentectomy or wedge resection in 161 patients (69.4%), and RFA in 69 patients (29.7%). Thus, a total of 302 patients underwent hepatic resection. After a median follow-up period of 19.5 months (range, 0.3 to 252.6 months), the median overall survival time was 27.2 months for all patients (95% confidence interval, 23.9 to 30.5 months). [Table 1](#t1-crt-2014-066){ref-type="table"} summarizes the clinical and pathologic characteristics of patients.

2. Analysis of data set
-----------------------

Multivariate Cox regression was applied to the patient data set to explore the significance of clinopathologic variables. The most influential variable for prognosis was DFI \< 12 months (from primary to discovery of liver metastasis). In terms of influence, DFI was followed by CEA level. Distribution of liver metastasis seemed significant, whereas the number of metastases, size of largest metastasis, and node-positive primary tumors were unrelated with prognosis ([Table 2](#t2-crt-2014-066){ref-type="table"}).

There was a highly significant relationship between the number and distribution of metastases. Although the number of metastases was not a significant factor for survival, it was reported as a significant prognostic factor in previous studies. Of the two, distribution of liver metastasis is likely to be a more robust factor since distribution of tumors is more easily determined compared to the absolute number of tumors.

PCA was applied to CEA, distribution of liver metastasis, and DFI as variables in the training data set. From 500 rounds of simulation, mean accuracy, specificity, and sensitivity values were calculated to be 0.54, 0.12, and 0.81, respectively. The results of PCA of the test data set were similar to those of the training set with respect to accuracy and sensitivity, but the property of specificity was not similar. In the case of Fong's criteria, the same three properties were 0.52, 0.47, and 0.65, respectively. Thus, the new PCA-based risk stratification method showed better performance in terms of accuracy and sensitivity, whereas specificity was lower than that of Fong's criteria ([Fig. 1](#f1-crt-2014-066){ref-type="fig"}).

The coefficients for distribution of liver metastasis were 0.9000793 in a single lobe and --0.7349271 in both lobes; for CEA, 0.3480379 for ≤ 200 ng/mL and --1.8054465 for \> 200 ng/mL; and for DFI, 0.1686233 for ≥ 12 months and --0.30495 70 for \< 12 months. This depicts the coefficients assigned by the PCA algorithm for each variable. All of the predictors were categorical, which means each coefficient in a variable corresponds to each category. The probability of survival increased in direct proportion to the PCA score. The PCA score ranged from --2.98 to 1.56. Based on the Q1 and Q3 quartiles, patients were stratified into three groups. The survival curves of each subgroup based on PCA score are shown in [Fig. 2](#f2-crt-2014-066){ref-type="fig"}. This analysis indicates that there were significantly different survival patterns among the three risk groups. In a pairwise comparison, groups 1 and 2 as well as groups 2 and 3 were significantly different in terms of survival patterns. Therefore, these stratification criteria can be a reliable tool for selecting patients for surgical resection of CLM.

Survival patterns between two vs. six groups based on Fong's criteria are shown in [Fig. 3](#f3-crt-2014-066){ref-type="fig"}. The survival patterns were significantly different ([Fig. 3A](#f3-crt-2014-066){ref-type="fig"}), although analysis showed that a four-group stratification (0-1, 2, 3, and 4-5) was more reliable than a six-group one.

Common factors in Fong's criteria and the PCA-based method were CEA and DFI. In the PCA method, distribution of metastases was used, as it was found to be a more significant factor than size and number of liver metastases. Three factors in the PCA method were very significantly different among the three risk groups, according to PCA score ([Table 3](#t3-crt-2014-066){ref-type="table"}). [Table 3](#t3-crt-2014-066){ref-type="table"} shows that age, sex, and histology were randomly distributed among the three risk groups. It is noteworthy that T and N stages are not related to the three risk groups. Fong's score was significantly associated with the PCA risk groups. The significance of metastasis size was weaker than the other five factors, although it was also significant. Although size of metastasis was significant among the three risk groups, it was not significant in the whole patient data set.

Discussion
==========

For patients with CLM, predictive models can help patients who are at increased risk of recurrent disease by offering appropriate treatment modalities, such as neoadjuvant, perioperative, or adjuvant chemotherapy, and support decision-making in terms of the timing of surgery \[[@b17-crt-2014-066]\].

The first predictive model was reported by Nordlinger et al. \[[@b11-crt-2014-066]\], and 11 additional prognostic scoring systems were developed since then. In terms of comparing the different methods, Merkel et al. \[[@b18-crt-2014-066]\] analyzed the predictive value of Fong's score, that of Nordlinger et al. \[[@b11-crt-2014-066]\], and TNM classification. They found that Fong's score was the most useful for prognosis and selecting adequate patients for hepatic resection. Reissfelder et al. \[[@b19-crt-2014-066]\] also found that both Fong's and Iwatsuki's scoring systems were effective in stratifying disease-specific survival among five prognostic scoring systems (Nordlinger score, Basingstoke index, Fong's risk score, Iwatsuki score, and Mayo Clinic scoring system) \[[@b13-crt-2014-066],[@b20-crt-2014-066]\].

Fong's method originally used five factors (nodal status of primary, DFI of \< 12 months, more than one metastasis, pre-operative CEA of \> 200 ng/mL, and tumor size of \> 5 cm) as criteria for clinical risk score (CRS) \[[@b20-crt-2014-066]\]. Patients with 0 points had an improved long-term outcome (p \< 0.001) with a 5-year actuarial survival rate of 60%, in comparison with that of 14% in patients with 5 points. This model is simple and easy to apply in a clinical setting.

Similar to previous reports of Mann et al. \[[@b21-crt-2014-066]\] and Arru et al. \[[@b22-crt-2014-066]\], Fong's CRS in our study was also highly predictive of survival when patients were grouped by scores of 0-2 and 3-5 (p \< 0.001); 5-year survival rates were reported as 29.1% and 10.6%, whereas 1-year survival rates were 90.4% and 67.1%, respectively. Fong's CRS was calculated for each patient, and the long-term outcomes of the six classes (0-5) were compared and worsened as Fong's score increased. Although Fong's CRS proved to be a useful instrument for identifying poor overall survival, a four-group stratification (0-1, 2, 3, and 4-5) was more reliable than a six-group one.

The PCA scoring system has good discriminatory ability. The PCA score can identify patients with a relatively favorable prognosis, demonstrating efficacy of therapeutic strategies. In our study, PCA score was based on retrospective analysis of patients at a single institution. Nonetheless, it retained its high prognostic significance when applied to an internal validation set of patients, and it compared favorably to Fong's CRS.

The PCA score is calculated using three clinical variables: CEA, DFI, and distribution of liver metastasis. In our study, the number of liver metastases was highly correlated with distribution of liver metastasis (data not shown). By using distribution rather than number or size, one is able to save time and avoid counting errors. Distribution of liver metastasis is considered as a prognostic factor in the H-number system of the Japanese Classification Colorectal Carcinoma \[[@b23-crt-2014-066]\]. In addition, recent effective chemotherapeutic agents and techniques can reduce the importance of tumor size, especially when metastases are confined to one lobe, thus making it easy to operate radically \[[@b17-crt-2014-066]\].

Prognostic scores should ideally be available for all patients during preoperative assessment and not restricted to liver resection \[[@b24-crt-2014-066]\]. Our scoring system showed more satisfactory and predictive efficacy in all patients with CLM. Importantly, the PCA method is simple and easy to apply, and all necessary clinical parameters can be easily obtained preoperatively through imaging and serum biochemical tests.

Conclusion
==========

Our results suggest that the PCA scoring system based on three variables may be useful for determining prognosis preoperatively, assisting in clinical decision-making, and designing future clinical trials for treatment of CLM patients. Prospective validation of this scoring system through a multicenter collaboration would confirm its utility.
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![Comparison of accuracy, specificity, and sensitivity in training and test data sets. Results are from 500 rounds of simulation. The sizes of training and test data sets were 396 (70%) and 170 (30%), respectively. The symbol×indicates accuracy, specificity, and sensitivity of Fong's criteria.](crt-2014-066f1){#f1-crt-2014-066}
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![Kaplan-Meier survival curves of risk groups defined by Fong's score. (A) Comparison of survival patterns between two vs. six groups. (B) Pairwise comparisons.](crt-2014-066f3){#f3-crt-2014-066}

###### 

Characteristics of patients

  Variable                           No. (%) (n=566)
  ---------------------------------- -----------------
  Age (yr)                           
   \< 60                             302 (53.4)
   ≥ 60                              264 (46.6)
  Median (range)                     58 (22-85)
  Gender                             
   Male                              382 (67.5)
   Female                            184 (32.5)
  Primary tumor T stage              
   T1                                5 (0.9)
   T2                                9 (1.6)
   T3                                467 (82.5)
   T4                                63 (11.1)
   NA                                22 (3.9)
  Primary tumor N stage              
   N0                                151 (22.7)
   N1                                197 (34.8)
   N2                                193 (34.1)
   NA                                25 (4.4)
  Tumor grade                        
   Well differentiated               54 (9.5)
   Moderately differentiated         422 (74.6)
   Poorly differentiated             54 (9.5)
   Mucinous                          2 (0.4)
   Signet ring cell                  14 (2.5)
   NA\'s                             20 (3.5)
  No. of metastases                  
   1                                 151 (26.7)
   \> 1                              415 (73.4)
  Size of largest metastasis (cm)    
   ≤ 5                               457 (80.7)
   \> 5                              109 (19.3)
  Distribution of liver metastasis   
   Single                            244 (43.1)
   Both                              322 (56.9)
  CEA (ng/mL)                        
   ≤ 200                             469 (82.9)
   \> 200                            97 (17.1)
  Disease-free interval (mo)         
   \< 12                             152 (26.9)
   ≥ 12                              414 (73.1)
  Fong\'s score                      
   0-2                               359 (63.4)
   0 (low)                           28 (4.9)
   1                                 128 (22.6)
   2                                 203 (35.9)
   3-5                               207 (36.6)
   3 (high)                          147 (26.0)
   4                                 49 (8.7)
   5                                 11 (1.9)

NA, not available; CEA, carcinoembryonic antigen.

###### 

Multivariate analysis for clinicopathological variables by Cox regression analysis

  Variable                                         Parameter   p-value                                                     Hazard ratio (90% CI )
  ------------------------------------------------ ----------- ----------------------------------------------------------- ------------------------
  Distribution of liver metastasis in both lobes   0.377       0.014[^\*^](#tfn3-crt-2014-066){ref-type="table-fn"}        1.459 (1.080-1.969)
  No. of metastasis \> 1                           0.249       0.153                                                       1.282 (0.912-1.804)
  Size of largest metastasis \> 5 cm               0.147       0.296                                                       1.159 (0.879-1.527)
  CEA \> 200 ng/mL                                 0.643       \< 0.001[^\*\*^](#tfn4-crt-2014-066){ref-type="table-fn"}   1.902 (1.416-2.554)
  Disease-free interval \< 12 mo                   0.684       \< 0.001[^\*\*^](#tfn4-crt-2014-066){ref-type="table-fn"}   1.982 (1.561-2.518)
  Node-positive primary tumor                      0.237       0.064                                                       1.267 (0.987-1.627)

CEA, carcinoembryonic antigen.

p \< 0.05,

p \< 0.001.

###### 

Comparison of clinopathologic variables among different risk groups

  Variable                           Group 3   Group2   Group1   p-value
  ---------------------------------- --------- -------- -------- ----------
  Age (yr)                                                       0.341
   \< 60                             88        119      95       
   ≥ 60                              91        101      72       
  Gender                                                         0.228
   Male                              124       154      204      
   Female                            55        66       63       
  Primary T stage                                                0.661
   T1                                1         3        1        
   T2                                2         5        2        
   T3                                149       177      141      
   T4                                18        30       15       
   NA                                9         5        8        
  Primary N stage                                                0.368
   N0                                50        55       46       
   N1                                60        84       53       
   N2                                52        73       68       
   NA                                17        8        0        
  Tumor grade                                                    0.215
   Well differentiated               17        20       17       
   Moderately differentiated         134       169      119      
   Poorly differentiated             19        16       19       
   Mucinous                          2         0        0        
   Signet ring cell                  1         7        6        
   NA                                6         8        6        
  No. of metastases                                              \< 0.001
   1                                 3         40       109      
   \> 1                              176       180      58       
  Size of largest metastasis (cm)                                0.012
   ≤ 5                               134       183      145      
   \> 5                              45        37       22       
  Distribution of liver metastasis                               \< 0.001
   Single                            2         75       167      
   Both                              177       145      0        
  CEA (ng/mL)                                                    \< 0.001
   ≤ 200                             88        214      167      
   \> 200                            91        6        0        
  Disease-free interval (mo)                                     \< 0.001
   ≥ 12                              52        151      167      
   \< 12                             127       69       0        
  Fong\'s score                                                  \< 0.001
   0-2                               34        166      159      
   0 (low)                           0         0        28       
   1                                 2         41       85       
   2                                 32        125      46       
   3-5                               145       54       8        
   3 (high)                          89        50       8        
   4                                 45        4        0        
   5                                 11        0        0        

Chi-square test was used. NA, not available; CEA, carcinoembryonic antigen.
